O n August 10, 2015, Turing Pharmaceuticals bought the marketing rights to pyrimetha mine (Daraprim), a decadesold firstline treatment for toxoplas mosis. The price of pyrimetha mine immediately increased by 5433%. Heavy scrutiny followed, and although Turing agreed to reduce the price, the drug re mains prohibitively expensive for many patients. Recently, at our hospital, an immigrant patient with a new diagnosis of HIV-AIDS and toxoplasmosis couldn't receive firstline therapy because of cost: the price for 100 pills was $75,000. The patient is currently receiving secondline therapy.
Unfortunately, the highly pub licized pyrimethamine acquisition is not unique. Prices have been quietly but dramatically increas ing for many older, offpatent drugs. Some of these medicines are considered essential by the World Health Organization (WHO) (see Table 1 ). In some cases, price hikes have disproportion ately affected vulnerable popu lations, making potentially life saving therapies unavailable to disadvantaged patients. It seems that a new business model has emerged: companies are acquir ing drugs in niche markets where there are few or no ther apeutic alternatives in order to maximize their profits. Unlike new brandname drugs, the pat ents of the drugs being targeted by this model expired years ago. These companies seem to have no interest in adding value to the health care system by developing new drugs.
The increased cost of albenda zole, an antiparasitic medication, is a case in point.
1 CorePharma acquired the U.S. marketing li cense for albendazole from Glaxo SmithKline in 2010 and subse quently sold it to a private equity group, Amedra Pharmaceuticals. Amedra then bought the only potential competitor available on the U.S. market, mebendazole, from Teva Pharmaceuticals. Since Amedra's acquisition, albenda zole's average wholesale price has increased by 3299%, from $5.92 per typical daily dose in 2010 to $201.27 in 2015.
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Other pharmaceutical compa nies have also used this strategy for manipulating the market. Vale ant Pharmaceuticals, a publicly traded company with 2014 reve nues of $8.25 billion, has taken a similar approach with several drugs. Valeant has been forth right about its goal of maximiz ing profits for shareholders while minimizing researchanddevelop ment (R&D) costs; the company currently spends 3% of its total revenue on R&D. Rodelis Thera peutics, a private company with little public transparency, also became notorious for buying the rights to cycloserine -a niche medication used in multidrug resistant tuberculosis -and im mediately increasing its price by more than 2000%. In response to a negative public reaction, Rodelis has since sold the drug back to its previous owner.
Many factors contribute to high pharmaceutical prices, including drug shortages, supply disrup tions, manufacturer consolida tions, and R&D costs. Though some companies that have pur chased and increased the price of niche medicines cite R&D as an What makes this business model particularly disturbing is that vulnerable patients -such as immigrants, refugees, and peo ple of low socioeconomic status -are often disproportionately affected, since many of the medi cations are for tropical or oppor tunistic infections. These patients often have limited or no access to insurance, or have access only through public programs, so al ready stark health disparities are compounded. In addition to pyri methamine, albendazole, and cy closerine, other antiinfective med ications that are often used in treating vulnerable patients have also had dramatic price increases. These include two drugs that are the firstline agents in their re spective classes: praziquantel (Bil tricide), used for schistosomiasis and other parasitic infections, and flucytosine (Ancobon), used for cryptococcal meningitis.
We believe that other older medications on the WHO Model List of Essential Medicines may be potential targets for opportun istic companies using this busi ness model. Many of these drugs lack therapeutic alternatives, tar get conditions that contribute to high morbidity and even mortal ity, are produced by one or few manufacturers, and exist in a mar ket that offers little incentive for new entrants. The WHO recom mends that items on the Model Although many of these drugs may be at risk for price increas es, antiinfective agents appear to be the most vulnerable. We identified 17 antiinfective medications on the WHO list that are produced by three or fewer manufacturers and have limited or no therapeutic equivalents (see Table 2 ). Seven of these treat tuberculosis; others are firstline treatments for leprosy, strongy loidiasis, malaria, or Chagas' dis ease. We speculate that these medications may experience dra matic price increases in the future, which would disproportionately affect vulnerable populations in the United States. Ironically, many of these agents are among the least expensive medications available elsewhere; pricecontrol mechanisms not available in the United States, such as govern mental ability to negotiate drug prices, are the primary reason for this discrepancy.
As questionable as the actions of companies such as Turing and Valeant may seem, they don't vio late antitrust laws. Even in cases in which anticompetitive behavior is suspected, the Federal Trade Commission (FTC) has been slow to respond or has failed to prove that the company's behavior was anticompetitive. 4 Recently, the FTC began investigating a "restricted drug distribution scheme" by Tur ing that may limit access to po tential genericdrug entrants. A congressional committee is inves tigating the actions of Valeant, Rodelis, and Retrophin.
Timely market solutions that promote competition are needed when high prices result from monopolies. Currently, there's lit tle incentive for a generic drug company to enter a niche market, especially given the expensive and lengthy process of gaining ap proval from the Food and Drug Administration (FDA). One recent development has been the FDA announcement that it will expe dite the review of abbreviated new drug applications for generic entrants when only one manu facturer exists. This move may encourage potential generic en trants that would otherwise have little incentive to enter a niche drug market with limited sales. In addition, the FDA could con sider eliminating user fees in 
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The Great War and Modern Health Care
Beth Linker, Ph.D. N early a century after the United States entered World War I, we can appreciate more than ever its profound effect on medical practice. For many peo ple, World War I conjures up im ages of men with shell shock, trench foot, and influenza. The burden of these conditions has tened the development of a host of new medical specialties as well as the construction of many hospitals and clinics. For these reasons, some historians believe World War I was responsible for ushering in modern medicine and the modern hospital.
1 An equally important -yet often overlooked -part of this history was the establishment of rehabilitation medicine, a specialty that helped pave the way for the eventual creation of the Veterans Admin istration.
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Six months after the United States declared war on Germany in April 1917, Congress passed the War Risk Insurance Act. Buried amid its actuarial language about insuring ships and soldiers' next of kin was a guarantee that all disabled soldiers would receive "rehabilitation and reeducation," making the care of disabled sol diers a federal mandate that would be paid for with federal dollars. For the first time in U.S. history, the Army Medical De partment recognized rehabili tation medicine as a necessary branch of its health care delivery system.
